- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03135197
German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.
January 4, 2021 updated by: University Hospital Muenster
The objective of the study is to document long term data on treatment with Migalastat under "real world" conditions.
The selection of patients is based on the SmPC/Fachinformation.
The study duration/patient will be 2 years.
Study Overview
Status
Completed
Conditions
Detailed Description
Phase 3 data should be confirmed in this study with long-term data.
- LVMI is expected to remain stable or to be ameliorated over an average of 24 months treatment duration. The LVMI reduction observed in patients followed up to 24 months is expected to be significantly reduced with a mean change of -6.6 g/m2 (-11.0, -2.1, 95% CI).
- eGFR [CKD-EPI] is expected to remain stable over an average of 24 months treatment duration. The long-term effect of Migalastat on eGFR is expected to be comparable to the decline over time in healthy adults. The annualized rate of change over this period is expected to be ≤1 mL/min/1.73 m2 in females and ≤3 mL/min/1.73 m2 in males.
- Significant reduction is expected in plasma lyso-Gb3 concentration at month 6, month 12 and month 24 following treatment with Migalastat.
- ERT-naïve patients treated with Migalastat are expected to show an improvement of GI symptoms (diarrhea) over 24 months.
- No progression of White Matter Lesions (WML) during treatment duration is expected.
- No higher frequency of stroke/transient cerebral ischemia during treatment duration is expected.
- Severity of neuropathic pain is expected to remain stable or to improve during treatment duration.
- Dosing/amount of symptomatic medications of neuropathic symptoms is expected to decrease during treatment duration.
Study Type
Observational
Enrollment (Actual)
75
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Münster, Germany, 48149
- Universtiy Hospital Münster
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 74 years (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
At therapy initiation adult male and female patients with FD will be identified, whose GLA mutations are amenable for a stimulation with Migalastat-HCl, and will be treated with Migalastat-HCl at the recommended dose continuously for 24 months according to the manufacturers' instructions (SmPC).
Description
Inclusion Criteria:
- Males and females, 16 to 74 years, diagnosed with Fabry disease.
- Amenable GLA mutation.
- Treatment with Migalastat (initiation of therapy according to recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Biegstraaten et al, Orphanet J Rare Dis. 2015;10:36. AWMF-Leitlinien Morbus Fabry, Diagnose und Therapie, Registernummer 030-134).
The following Inclusion criteria refer to the time of Migalastat initiation (T0):
- ERT naïve (patients with signs of organ involvement (kidney, heart and/or CNS signs) to be considered for ERT following the European Consensus Guidelines on ERT (Biegstraaten et al 2015) or patients with neuropathic pain not controlled with pain medication or patients with GI symptoms not relieved with standard medication or ERT switch patients (under ERT for ≥12 months).
- Estimated GFR (eGFR, CKD-EPI formula) at screening ≥30 ml/min/1.73 m2
- Subjects taking no ACE inhibitors, ARBs, or renin inhibitors or are on a stable dose for at least 4 weeks before screening.
- Subjects taking no analgesics/antidepressants or are on a stable dose for at least 4 weeks before screening.
Exclusion Criteria:
- Patient has a non-amenable GLA mutation or the mutation A143T or D313Y (for verification of amenable mutations please refer to: www.GalafoldAmenablityTable.com or to the "Fachinformation").
- Patient is unwilling to give informed consent.
- Patient is unable to comply with the clinical protocol.
- Patients on co-medication: Galafold plus Enzyme Replacement Therapy (ERT)
- Pregnant or breast feeding women.
The following Exclusion criteria refer to the time of Migalastat initiation (T0):
- Patients on dialysis
- Patient has a clinically significant organ disease (e.g. cancer in the past 5 years) that in the opinion of the investigator would preclude participation in the trial.
- Patients with a history of organ transplantation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Migalastat
Migalastat administered according to SmPC
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LVMI
Time Frame: two years
|
Primary endpoint of the observational study is the change in left ventricular mass index (LVMI) over two years.
|
two years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GFR
Time Frame: 24 months
|
Change in GFR over 24 months
|
24 months
|
Cerebral ischemia or stroke.
Time Frame: 24 months
|
Incidence of transient/manifest cerebral ischemia or stroke over 24 months.
|
24 months
|
Neuropathic Pain (GCPS)
Time Frame: 24 months
|
Change in severity of neuropathic pain measured by Graded Chronic Pain Scale (GCPS)
|
24 months
|
Neuropathic Pain (NPSI)
Time Frame: 24 months
|
Change in severity of neuropathic pain measured by Neuropathic Pain Symptom Inventory (NPSI) Score (items are quantified on a (0-10) numerical scale).
|
24 months
|
Fabry Disease Severity (MSSI)
Time Frame: 24 months
|
Change in disease severity measured by Mainz Severity Score Index (MSSI)
|
24 months
|
Fabry Disease Severity (DS3)
Time Frame: 24 months
|
Change in disease severity measured by the Disease Severity Scoring System (DS3)
|
24 months
|
Lyso-Gb3
Time Frame: 24 months
|
Change in Lyso-Gb3
|
24 months
|
White Matter Lesion load
Time Frame: 24 months
|
Change of White Matter Lesion load (quantified by WML volumetry [ml]).
|
24 months
|
Cerebral microbleeds/hemorrhagic lesions.
Time Frame: 24 months
|
Stabilization of cerebral microbleeds/hemorrhagic lesions.
|
24 months
|
Gastrointestinal symptoms
Time Frame: 24 months
|
Change in gastrointestinal symptoms (gastrointestinal symptoms rating scale, GSRS).
|
24 months
|
Quality of life (SF-36)
Time Frame: 24 months
|
Change in quality of life (Short Form (SF-36) Health Survey: 36-item, patient-reported survey of patient health).
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Eva Brand, Prof., University Hospital Muenster
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 8, 2017
Primary Completion (ACTUAL)
June 30, 2020
Study Completion (ACTUAL)
June 30, 2020
Study Registration Dates
First Submitted
April 20, 2017
First Submitted That Met QC Criteria
April 25, 2017
First Posted (ACTUAL)
May 1, 2017
Study Record Updates
Last Update Posted (ACTUAL)
January 5, 2021
Last Update Submitted That Met QC Criteria
January 4, 2021
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Lipid Metabolism Disorders
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Sphingolipidoses
- Lysosomal Storage Diseases, Nervous System
- Cerebral Small Vessel Diseases
- Lipidoses
- Lipid Metabolism, Inborn Errors
- Fabry Disease
Other Study ID Numbers
- Fabry_Migalastat
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fabry Disease
-
CENTOGENE GmbH RostockCompletedFabry Disease | Anderson-Fabry Disease | Fabry´s DiseaseArgentina, Belgium, Croatia, Czechia, Denmark, France, Germany, United Kingdom
-
Wuerzburg University HospitalTakedaEnrolling by invitationLysosomal Storage Diseases | Fabry Disease | Fabry Disease, Cardiac Variant | HCM - Hypertrophic Cardiomyopathy | Anderson Fabry DiseaseGermany
-
University Hospital, RouenUnknownAnderson-Fabry DiseaseFrance
-
Sangamo TherapeuticsEnrolling by invitationFabry Disease | Fabry Disease, Cardiac VariantUnited States, Australia, United Kingdom
-
Amicus Therapeutics France SASActive, not recruitingFabry Disease | Anderson Fabry DiseaseFrance
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingFabry Disease | Fabry Disease, Cardiac VariantNetherlands
-
Taipei Veterans General Hospital, TaiwanSanofiUnknownFabry Disease, Cardiac Variant
-
University of CambridgeSanofiRecruiting
-
Shaare Zedek Medical CenterJohannes Gutenberg University MainzCompleted
-
Wolfson Medical CenterUnknownFabry Disease in the Young StrokeIsrael